諾和諾德公佈 Wegovy 的新健康益處
Novo Nordisk shares new health benefits of Wegovy
Updated at: June 7, 2026 at 05:30 AM
諾和諾德正在重塑我們看待Wegovy的方式，這是一種最初主要以減重聞名的藥物。
Novo Nordisk is reshaping how we view Wegovy, a medication originally known primarily for weight loss.
近期的數據，包括來自具有里程碑意義的SELECT試驗中的洞見，揭示了Wegovy提供的健康益處遠不止於減輕體重。
Recent data, including insights from the landmark SELECT trial, reveal that Wegovy offers significant health benefits that extend far beyond shedding pounds.
對於患有肥胖症和心血管疾病的患者，該藥物已被證實能將心臟病發作和中風等重大事件的風險降低20%。
For patients with obesity and cardiovascular disease, the drug has been shown to reduce the risk of major events like heart attacks and strokes by 20%.
有趣的是，這些心臟健康方面的改善在治療三到六個月後就顯現出來，這暗示了除單純減重之外的機制也在起作用。
Interestingly, these heart-health improvements appear as early as three to six months into treatment, suggesting that mechanisms beyond simple weight loss are at play.
除了心臟健康，研究人員正發現司美格魯肽——Wegovy的活性成分——可能有助於管理各種與肥胖相關的共病症。
Beyond heart health, researchers are discovering that semaglutide—the active ingredient in Wegovy—may help manage various obesity-related comorbidities.
研究顯示該藥物對於阻塞性睡眠呼吸中止症、氣喘相關症狀、高血壓和肝臟健康等病症具有潛在的改善作用。
Studies indicate potential improvements for conditions like obstructive sleep apnea, asthma-related symptoms, hypertension, and liver health.
這些益處很可能與該藥物降低全身性發炎的能力有關。
These benefits are likely tied to the drug’s ability to reduce systemic inflammation.
儘管許多這些新興數據來自探索性分析，醫學界正在轉變其觀點。
While much of this emerging data comes from exploratory analyses, the medical community is shifting its perspective.
Wegovy日益被認定不僅僅是一種減重工具，而是一種針對伴隨肥胖而來的相互關聯健康風險的綜合治療方案。
Wegovy is increasingly recognized not merely as a weight-loss tool, but as a comprehensive therapy for the interconnected health risks that accompany obesity.
這種演變標誌著現代代謝醫學的一個重要里程碑。
This evolution marks a significant milestone in modern metabolic medicine.
